BioRestorative Therapies Inc. (BRTX), a clinical-stage regenerative medicine company developing stem cell-based therapies and products, is scheduled to host a conference call at 10:30 am EST today to provide a clinical pipeline update.
The company's lead drug candidate is BRTX-100, a novel cell-based therapeutic engineered to target areas of the body that have little blood flow. BRTX-100 is being tested in a phase II trial in patients with chronic lumbar disc disease.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.